STOCKHOLM, November 23rd, 2020 – On November 25th, 2020, at 02:00 am (CET), investors, analysts and journalists are invited to participate in a digital company presentation. Moberg pharma recently announced its intention to distribute its subsidiary OncoZenge through a Lex ASEA distribution before listing the company on Nasdaq First North Growth Market, as well as securing financing both for OncoZenge and Moberg Pharma.
The teleconference will be hosted by Moberg Pharmas’s CEO Anna Ljung and Chairman of the Board Peter Wolpert. The presentation will be held in Swedish.
Date: Wednesday November 25th, 2020
Time: 12:00 am – 1:00 pm (CET)
To participate in the conference, please use the following link:
https://zoom.us/webinar/register/WN_EQZwZq8dTiugFJjacf7IeQ
Presentation material will be made public on:
http://www.mobergpharma.com/investors/calendarpresentations
About Moberg Pharma, www.mobergpharma.com
Moberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The company’s main asset, MOB-015, is a novel topical treatment for onychomycosis, with recently completed phase 3 trials in more than 800 patients. The pipeline also includes the late-stage asset BUPI for pain relief in oral mucositis, intended to be spun off in the separate company OncoZenge. Clinical data generated for both assets indicate that they have the potential to become market leaders in their respective niches. Moberg Pharma is headquartered in Stockholm and the company’s shares are listed on the Small Cap list of the Nasdaq Stockholm (OMX: MOB).
About OncoZenge, www.oncozenge.se
OncoZenge AB (publ) is a Swedish pharmaceutical company founded in 2020 through a spin-off from Moberg Pharma AB. The company collaborates with leading clinicians from Hvidovre Hospital in Denmark. OncoZenge develops better products for supportive care of cancer patients. Preparations are underway for Phase 3 of BupiZenge®, after leading Phase 2 data for pain relief in patients with oral mucositis.
For additional information, please contact:
Anna Ljung, CEO, Phone: + 46 70 766 60 30, e-post: anna.ljung@mobergpharma.se
Mark Beveridge, VP Finance, Phone: + 46 76 805 82 88, e-post: mark.beveridge@mobergpharma.se